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Abstract
Coronary artery disease can be treated by implanting a stent into the blocked region of an artery, thus enabling
blood perfusion to distal vessels. Minimally invasive procedures of this nature often result in damage to the arterial
tissue culminating in the re-blocking of the vessel. In an effort to alleviate this phenomenon, known as restenosis,
drug eluting stents were developed. They are similar in composition to a bare metal stent but encompass a coat-
ing with therapeutic agents designed to reduce the overly aggressive healing response that contributes to resteno-
sis. There are many variables that can influence the effectiveness of these therapeutic drugs being transported
from the stent coating to and within the artery wall, many of which have been analysed and documented by
researchers. However, the physical deformation of the artery substructure due to stent expansion, and its influence
on a drugs ability to diffuse evenly within the artery wall have been lacking in published work to date. The paper
highlights previous approaches adopted by researchers and proposes the addition of porous artery wall deforma-
tion to increase model accuracy.
Introduction
Atherosclerosis is a degenerative disease that affects cor-
onary, carotid and other peripheral arteries in the body.
Disease formation can occur as early as childhood with
the development of fatty streaks within the artery wall.
As the aging process progresses these fatty streaks accu-
mulate becoming larger lipid deposits within the artery
and are detrimental to the smooth operation of the vas-
culature. Occlusions ensuing from aggressive plaque
progression can often culminate in an ischemic attack,
such as an apoplectic attack or a myocardial infarction
[1-3]. There are a number of interventional procedures
available to the clinician but the successful emergence
of drug eluting stents (DES) has seen them become the
preferred choice, so much so that by the beginning of
2006 more than 8 out of 10 coronary stents were DES
[4] at a cost of between $4 and $5 billion annually [5].
When used in conjunction with balloon angioplasty, a
bare metal stent increases post procedural patency by
acting as a scaffold for the artery wall. Stenting however
causes arterial injury resulting in the restenosis of a
large portion of stented arteries. In an attempt to reduce
the number of patients that warranted re-interventional
procedures, stents were coated with therapeutic agents
to combat restenosis and became known as DES. Drug
loaded polymer coatings on the stent surface treat the
injuries inflicted on the artery wall upon stent implanta-
tion. Once these drugs are within the wall they act
against the arteries natural healing mechanisms in order
to reduce the possibility of a recurring blockage. Quite
often, when a DES is implanted in an artery a portion of
the drugs used to target restenosis are washed away in
the blood stream. Therefore it is imperative to under-
stand all of the mechanisms that influence drug trans-
p o r tf r o mt h ed e v i c es ot h a tD E Sc a nb ed e s i g n e dt o
optimise their capabilities. This study began by defining
the current knowledge base pertaining to drug transport
within the artery wall from DES. However, the funda-
mental aspect concerning the mechanical deformation
of the porous artery wall, and its influence on drug con-
centrations within, had not been reported in computa-
tional DES studies to date.
Coronary artery disease
Coronary artery disease (CAD) has been intrinsically
linked to atherosclerosis since the early 20
th century
[1,6-8] and refers to the localisation of disease within
the coronary arteries. CAD is the foremost cause of
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and is responsible for approximately 700,000 deaths in
the United States of America annually [2,10]. Regular
exercise and a balanced diet have been shown to influ-
ence CAD development but it is the concentration of
lipid rich cholesterol in the blood that is considered the
most important factor [8,14-18].
There are a number of ways to treat CAD such as
coronary artery bypass graft (CABG) surgery. Although
the long term patency rates of these grafts are moderate,
CABG surgery remained the gold standard in the treat-
ment of CAD until 1977 when the first percutaneous
transluminal coronary angioplasty (PTCA) surgery was
p e r f o r m e d[ 1 9 , 2 0 ] .I tw a sd i s c o v e r e dt h a tas u b s t a n t i a l
percentage of patients, reported to be between 30 and
60%, experienced recurrent ischemia due to the re-
blocking of the artery (restenosis) within 6 months after
PTCA. Restenosis is attributed to the mechanical injury
caused by over dilating a device within the vessel result-
ing in neointimal hyperplasia, elastic recoil and negative
arterial remodelling [4,19-26]. The next major advance
in the field of minimally invasive interventional cardiol-
o g yc a m ei nt h ef o r mo ft h ec o r o n a r ya r t e r ys t e n t
(CAS). CAS reduced failure rates to between 10 and
40% [4,7,9,13,19-23,25,27-31] because it virtually elimi-
nates elastic recoil and negative remodelling of the
artery [32,33].
Restenosis and its mechanisms
Restenosis can best be described as an overly aggressive
inflammatory healing response in the artery wall due to
the mechanical injury inflicted by balloon expansion. It
is quantified by the reduction of lumen size after an
intravascular interventional procedure [34]. Inflation of
a balloon catheter within a diseased artery pushes the
plaque against the artery wall, forcing the artery to
stretch and often results in the fracture of not only the
plaque but in some cases can damage the artery wall
also [32,35]. Similar damage ensues when a stent is used
in conjunction with a balloon catheter, however a stent
can cause excessive injury, increasing neointimal forma-
tion, by penetrating the media and in extreme cases
going as deep as the adventitial layer of the artery
[22,32].
The development of restenosis can be influenced by
three processes after PTCA, namely elastic recoil, arter-
ial negative remodelling and neointimal hyperplasia
[7,19,21-23]. Restenosis in up to 60% of patients under-
going PTCA can be attributed to the extent of elastic
recoil and arterial modelling. Elastic recoil can occur
within 1 hour of PTCA and is attributed to the passive
recoil of the elastic medial layer of the artery. Positive
remodelling of the artery wall occurs naturally in ather-
osclerotic arteries as a compensatory response to plaque
formation and limits the narrowing of the vessel lumen.
There are contrasting opinions on the mechanisms
behind arterial remodelling [19] but the negative remo-
delling of the artery demonstrated after PTCA has been
shown to contribute to restenosis by narrowing the
artery. Both elastic recoil and arterial modelling are
believed to be virtually eliminated when angioplasty is
used in conjunction with a stent. Neointimal hyperplasia
occurs in response to arterial injury, whereby platelets
and fibrin are deposited on the wound. Growth factors
are consequently released from the platelets which can
promote smooth muscle cell (SMC) migration from the
media. The result of this is a build up of SMC, extracel-
lular matrix (ECM) and macrophages at the injured site
over several weeks. It is here that cellular division takes
place which appears to be essential for the development
of restenosis [4,19,22,24,32,33,36-39]. Reduction of SMC
proliferation is of the utmost importance if the inci-
dence of restenosis is to be reduced [18,21,22,27,37,
40,41]. The second generation of stent, the DES family,
was developed with a coating of anti-restenotic agents
aimed at alleviating the initiation of SMC proliferation
to the site of injury after stent implantation.
Drug eluting stents
Long term clinical trial results for this technology are
not widespread, although several studies have reported
on the performance of these devices in coronary arteries
in the short to medium term. Some trials have indicated
that the incidence of myocardial infarction and death
are lower when DES are used [42,43] while other studies
suggest that DES and BMS perform similarly [44]. The
contrasting outcomes from such trials raise questions
regarding the effectiveness of DES which has resulted in
an increased effort by researchers to develop a means of
predicting the behaviour of these devices in the short to
long term.
As the primary use of these devices to date has been
in the coronary arteries, this application will form the
focus of the information presented. Mechanically speak-
ing, stents offer far superior structural support than
PTCA but the adverse biological responses need to be
understood in order to address the mechanisms of
injury that lead to restenosis. As described above, it is
generally accepted that one of the main causes of reste-
nosis following bare metal stent (BMS) implantation is
SMC proliferation and migration from the media to the
injured site. Thus, the curtailment of this excess SMC
proliferation has been identified as the focal point in
combating restenosis [18,21,22,27,37,40,41]. Attempts at
systemic drug delivery to inhibit restenosis after stenting
failed because effective dosing levels had a toxic effect
and could not be tolerated by the patients [22,45].
Therefore the concept of local drug delivery using a
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this. The site specific local delivery of drugs from DES
offers an advantage over systemic delivery because the
drug is applied to the injured vessel at the exact location
and time that damage occurs.
The anti-restenotic coating on a DES inhibits the for-
mation of neointimal hyperpl a s i ab ys u p p r e s s i o no ft h e
inflammatory reaction, platelet activation and SMC pro-
liferation. Most of the drugs explored originally were
used as agents for anti-transplant rejection or as immu-
nosuppressive drugs [21,46]. In April 2003 the first DES
to gain commercial approval from the Food and Drug
Administration (FDA) in the United States was the
Cypher™ stent, which was developed by Cordis Corpora-
tion (Miami, FL. USA) and used a drug called sirolimus.
Boston Scientific’s( N a t i k ,M A .U S A )T a x u s ™ family of
stents were the second DES platform approved by the
FDA in March of the following year. The drug employed
on the Taxus stent was called paclitaxel [47]. These first
generation DES had a profound effect on reducing reste-
nosis rates compared to BMS models. Clinical trials car-
ried out on the Cypher stent (SIRIUS-1) showed
restenosis rates of 8.9% after 8 months compared to
36.6% for BMS in the same study. Likewise the TAXUS
IV trials heralded a dramatic reduction in restenosis
rates when compared to BMS after 9 months, 7.9% ver-
sus 26.6% respectively [47].
In 2008, results were published from the SPIRIT-III
clinical trials comparing Abbott Vascular’s next genera-
tion everolimus DES, the Xience-V, with Boston Scienti-
fic’s Taxus Express2 paclitaxel DES. The trial suggested
that angiographic in-segment late loss was significantly
less for the Xience-V stent than for the Taxus Stent.
The trial also showed a dramatic reduction in major
adverse cardiac events for the Xience-V stent compared
to the Taxus stent, recording a 43.2% and 41.7% reduc-
tion after 9 and 12 months respectively [30]. Reasons
for this may be the allocation of drug type or the design
of the stent and its impact on the artery wall.
Arterial mass transport
Mass transport (MT) refers to the transfer of mass, i.e.
the species of interest which is drugs in the case of DES,
from regions of high concentration to low concentra-
tion. In the absence of a free flowing system the pre-
sence of these concentration gradients induces diffusion,
e.g. between the DES and the artery wall. MT can be
broken up into two types within the human vasculature.
Firstly blood side MT (BSMT) refers to species trans-
port within the vessel lumen and is subject to the hae-
modynamics therein. The flowing nature of blood
within the lumen will limit the DES ability to deliver
therapeutic quantities of drug to the wall via BSMT, as
it effectively washes the drugs away from the injured
area. It is only in regions of high blood flow recircula-
tion, e.g. immediately behind a stent strut, that it is pos-
sible for a sufficient amount of drug to remain for long
enough to result in a therapeutic response.
The second mode is in relation to transport within the
wall of the artery, referred to as wall side MT (WSMT).
Along with the properties of the species being trans-
ported within the artery wall, WSMT depends on the
structural condition of the wall itself, i.e. a damaged inti-
mal layer could facilitate accelerated MT through to the
medial layer [48]. The accurate modelling of MT within
the artery wall requires a keen knowledge of the arterial
substructure. Although a pressure induced velocity
exists across a healthy artery wall, DES are implanted in
arteries that are heavily blocked and in warrant of inter-
vention. If the plaque were dense enough the transmural
velocity would reduce to approximately zero. This would
reduce the Peclet number and indicate a diffusion domi-
nated mass transport environment within the artery
wall.
The arteries themselves are not simply cylindrical
mono-layered vessels. The wall consists of a complex
multilayer porous substructure with the interstitial areas
comprising predominantly of plasma. In a healthy artery
this substructure (figure 1) is comprised of three con-
centric layers; the tunica intima, the tunica media and
the tunica adventitia. The tunica intima is the innermost
layer, comprising of a single layer of endothelial cells
and a subendothelial layer mainly consisting of delicate
connective tissues and collagen fibres. The outer bound-
ary of the tunica intima is surrounded by an elastic tis-
sue with fenestral pores known as the internal elastic
lamina (IEL) [49]. The medial layer consists primarily of
concentric sheets of SMC and elastic connective tissue.
This configuration of SMC sheets enable the artery wall
to contract and relax. The tunica media and the tunica
adventitia are separated by another thin band of elastic
fibres known as the external elastic lamina (EEL). The
outermost layer of the artery, the tunica adventitia, com-
prises of connective tissue fibres and some capillaries.
These fibres blend into the surrounding connective tis-
sues and aid in stabilising the arteries within the body
[17,49,50]. However, DES are deployed in arteries that
have a significant amount of plaque which will undoubt-
edly have a bearing on arterial MT outcomes. The stent-
ing procedure itself will also have an impact on MT due
to the damage caused to the intimal layers upon stent
deployment and subsequent thrombus build up around
the stent. The greater the volume of clot that surrounds
the strut, without being debilitating to blood flow, and
the closer the strut is to the artery wall, provokes more
optimal conditions for arterial MT.
Computational studies can give us vital information
regarding the MT capabilities of a DES. Once the artery
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to computational models in order to assess their impact
on the stents performance. Parameters such as the
degree of artery wall damage and strut embedment,
drug type, polymer characteristics and the extent and
type of disease are documented in the following section.
Although these studies give us an insight as to the beha-
viour of these variables, no published work to date con-
tains a complete computational DES MT model because
they all fail to incorporate the influence of the stent
compressing the porous artery wall.
Computational research
Spatial fluctuations in arterial drug concentration will
depend on a host of variables such as the drug and poly-
mer characteristics, stent design and also the structure
of the artery wall and the plaque encased therein.
Computational prediction of drug mass transport from a
DES is a powerful means of evaluating the effectiveness
of stent design before a stent is taken to clinical trial.
This provides the manufacturer with a level of controll-
ability, enabling the production of a DES that will offer
sufficient dosage of therapeutic agents to the injured
vessel while reducing the possibility of toxicity in loca-
tions of greater stent arterial coverage, e.g. at strut
junctions.
The theoretical description and subsequent computa-
tional representation of mass transport from a DES into
the artery wall presents significant challenges to
researchers due to the complex interactions of all the
physical and chemical processes taking place. Therefore
it is necessary to make simplifications and assumptions
in order to represent arterial MT and solve the problem
computationally. One such simplification is to neglect
Figure 1 Artery wall structure.
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to effect species uptake within the wall. They are often
neglected under the assumption that they become
denuded upon stent implantation, leaving the stent strut
in direct contact with the medial layer. This assumption
is commonplace because it is the drug distribution
within the medial layer that is ultimately responsible for
reducing restenosis. From a computational perspective
one of the more common ways to reduce the demand
on numerical solvers is to decrease the degrees of
dimensionality of the system from 3-D to 2-D and
finally a 1-D analysis if need be.
In 2008, Zunino et al. [51] developed a comprehensive
representation of a DES within an artery. The computa-
tional model was 3-D in nature and analysed the stent
from a mechanical (upon balloon expansion) to a fluid
dynamic (blood flow over the stent struts) perspective.
A number of stent strut cells were modelled in contact
with the artery and the concentration distribution was
analysed. Reducing a models dimensionality saves on
computational demands but not necessarily at the
e x p e n s eo fr e a l i s t i cr e p r e s e n t ation. Balakrishnan et al.
published work [52-54] which demonstrated the pro-
gression of their 2-D computational DES transport
model. The 2-D computational model presented in their
most recent publication [52] may be perceived to be
more realistic than the 3-D one proposed by Zunino et
al. [51] due to the consideration of mural thrombus sur-
rounding the stent struts. Likewise 1-D MT analysis can
be effective in quantifying drug concentrations within
the wall. Although dimensionally inferior, the work of
Pontrelli and de Monte [55] describe MT through mul-
tiple layers, a porous artery medial layer and a porous
polymer coating with polymer top coat (similar in com-
position to the Cypher stent [56]). The application of a
porous artery wall subdomain is more representative of
an actual artery wall than the homogeneous walls mod-
elled in the aforementioned 2-D and 3-D examples.
Influence of drug type on mass transfer
The hydrophobicity of drugs plays an important role in
local drug concentrations from stents [48]. Hydrophilic
drugs were found to wash away more quickly due to
their tendency to follow transmural fluid movement,
while hydrophobic drugs can attain higher concentra-
tions in the artery wall due to their preferential binding
to artery wall structural proteins. Hydrophilic drugs,
such as heparin, were initially sought as the answer to
combating restenosis but proved unsuccessful due to
lower heterogeneous tissue concentrations than hydro-
phobic drugs. In contrast, drugs of a hydrophobic nat-
ure, such as paclitaxel and sirolimus, are advantageous
due to their retention of high therapeutic doses within
the wall [48]. Hwang et al. [48] suggest that diffusion in
the media was anisotropic, with the circumferential dif-
fusion being approximately 10 times greater in magni-
tude than the transmural value. In 2004, Zunino [57]
conducted a numerical analysis comparing the employ-
ment of contrasting drug types, heparin and taxus.
Heparin diffusivity within the wall was almost 3 times
that of taxus. It was found that taxus accumulated more
easily than heparin in the region surrounding the strut
because of its tendency to bind with the tissue and its
lower diffusivity. Zunino [57] recorded a 70% loss of
heparin into the blood after 6 hours while for the same
time period only 60% was lost for the taxus simulation.
Instead of attributing drug specific diffusion values in
their analysis some researchers, such as Mongrain et al.
[31], describe the concentration distribution in the
artery wall for a range of arbitrary diffusion values.
Their results indicate that the amount of drugs that
accumulate within the artery wall depend on the values
of the diffusion coefficient in the wall and the polymer
respectively. Similar to Zunino [57], Mongrain et al. [31]
deduced that drug accumulation within the wall was
greater for smaller artery wall diffusivities as this
reduces the drugs ability to leave the artery wall once
embedded.
Influence of strut positioning on mass transport
Strut positioning within an artery will ultimately be
responsible for local fluctuations in arterial drug con-
centration. Unlike some of the first generation stents,
with their uniformly distributed strut arrangement, the
newer stents have irregular cell designs that enable
greater flexibility while retaining structural stability. This
generally results in an inhomogeneous distribution of
stent struts in the circumferential and longitudinal
directions. Hwang et al. [48] examined the effect of strut
placement on a circumferential artery cross section
(comparing 8 evenly with 8 randomly placed struts).
Although mean tissue concentration remained the same
regardless of strut position, the local concentrations,
which predominantly determine biological response, are
heavily dependent on strut spacing. Balakrishnan et al.
[54] investigated the influences of multiple struts, strut
spacing and the incidence of overlapping stent struts in
a 2-D longitudinal artery cross section. A concentration
of unity was placed on the stent surface and no polymer
was used, although this is not ideal it does give a good
approximation of the effect of the aforementioned vari-
ables after stent implantation. The highest wall concen-
tration for longitudinal strut distribution was witnessed
where the struts were closest together (1 strut length
spacing apart), while a gap of 7 strut lengths resulted in
individual peaks in concentration under each strut that
increased slightly along the length of the model. For the
case of overlapping struts, twice as much drug is
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struts is altered. Balakrishnan et al. [54] discovered that
peak concentrations resulting from different overlapping
strut configurations rise by 22-34% compared to the sin-
gle strut case. The incidence of overlapping struts where
one of them was fully embedded within the wall resulted
in an increase of 45% in peak concentration. Mongrain
et al. [31,58] conducted more thorough research relating
to strut embedment and its effect on concentration
within the wall. Degree of strut embedment was found
to play a significant role in arterial concentration within
the first 3 days of deployment. At 250 μm beneath the
endothelium significantly higher concentrations were
witnessed directly beneath any single strut compared to
levels measured half way between two struts at the same
depth. The study showed that after 3 days the wall con-
centrations normalised at both points due to the reduc-
tion of drugs being released from the polymer coating
[31].
Influence of polymer type on mass transport
Stent coatings play a vital role in the regulation of drug
release from within. Careful consideration must be
observed when allocating a polymer as a drug carrier for
a DES. In this study the design of polymer coatings is
not discussed in detail as these designs will ultimately
only contribute to the diffusivity value of the drugs from
the device. The following section reviews how varying
polymer drug diffusivity (a consequence of polymer
coating design) affects mass transport. If the polymer is
not biocompatible an inflammatory response ensues
[22,46] and in certain cases the development of intimal
hyperplasia can be doubled when uncompatable poly-
mers are used compared to a controlled substance [23].
Each biologically viable polymer must also be able to
endure the stresses exerted with stent deployment in the
arteries and must be able to resist cracking and peeling.
They also have to maintain their physiochemical proper-
ties after sterilisation. There have been numerous poly-
mers suggested as possible suitors for storing drugs on a
DES but most of the polymers actually used on com-
mercial DES are proprietary. Drug release rates can be
altered with the addition of an extra layer of covering
polymer to modulate between slow and fast release for-
mulations. This adds an extra degree of complexity
when designing functional DES.
Mongrain et al. [31,58] analysed how drug diffusivities
within the polymer coating can impact drug concentra-
tion within the artery wall. While lower effective drug
diffusivity values in the artery wall are favourable for
uptake within the wall, having a low drug diffusivity in
the polymer can be just as influential on the outcome.
After 3 days an arterial concentration of 30.51% was
achieved when the drug diffusivity in the polymer
(Dpolymer)w a s1×1 0
-14m
2/s but when Dpolymer was
increased to 1 × 10
-12m
2/s the arterial concentration
reduced to 3.55% (in both cases Dwall was 1 × 10
-14m
2/s).
Balakrishnan et al. [53] reiterates this finding but there
are optimal polymer diffusivities that promote favourable
arterial drug concentrations. At the extremes of drug dif-
fusivity in the polymer coating, drug can be released so
rapidly that it exceeds tissue absorption rate and the
majority of drug can be lost to the blood stream. On the
other hand if the drug is released too slowly it will not
effectively penetrate the artery wall at levels sufficient to
be therapeutic. The influence of dose and polymer thick-
nesses on the drug distribution within the wall was
demonstrated by Balakrishnan et al. [53]. Drug release
from thinner coatings with high concentrations was pre-
dicted to be fast initially but subject to a rapid decline
when compared to a thicker polymer coating with lower
concentration.
Balakrishnan et al. [53] and Mongrain et al. [31,58]
modelled their stent struts with a polymer matrix coat-
ing in which the drug is uniformly dispersed (figure 2A).
The drug molecules further away from the surface have
a longer migration distance, resulting in a lower drug
release rate over time [56]. This type of configuration
can be seen on Boston Scientific’sT a x u s ™ stents.
Another popular method of controlled release is a reser-
voir coating (figure 2B) as seen on Cypher™ stent devel-
oped by Cordis. In this configuration the stent is coated
w i t had r u gl o a d e db a s ec o a tw h i l eat h i nt o pc o a ta c t s
as a rate controlling membrane [56]. Varying the diffu-
sivity of the top coat regulates the transition of drug
from the base coat to the artery wall.
Influence of thrombus on mass transport
Hwang et al. [59] were among the first to explore the
influence of thrombus height, width and type on the
arterial drug uptake. Stents are often deployed at sites of
thrombus and after implantation a clot will inevitably
develop once the struts become covered with plasma
proteins. In most cases this will not be angiographically
present or clinically evident but even a fine layer of clot-
ting blood deposited on the surface of the DES can alter
drug distribution within the wall. The presence of clot
alters the local environment of the stent strut and the
physiological transport forces that regulate arterial
uptake and retention. Late stent thrombosis has been
reported to occur at a rate of 0.6% each year after DES
implantation for up to 3 years [52] and strut position
within any clot will have a major influence on the arter-
ial uptake. The greater the mass of clot over the strut
and the closer the strut is to the wall tends to provoke
more optimal conditions for drug delivery. Hwang et al.
[59] discovered that in this configuration concentration
distribution in the wall can be 30 fold higher than
O’Connell et al. BioMedical Engineering OnLine 2010, 9:15
http://www.biomedical-engineering-online.com/content/9/1/15
Page 6 of 12situations where no clot is present. Similarly thrombus
clots between the strut and the artery wall act as a buf-
fer layer and reduce wall concentrations. Clot diffusiv-
ities higher than that of the arterial tissue can result in
drug transfer from the stent to the artery wall at a rate
faster than the wall can absorb. This results in the unde-
sirable loss of drug to the circulatory system. Clots with
diffusivities equal to or lower than the arterial wall
transport drugs to the wall at a rate where the wall can
effectively absorb the drugs, thus reducing drug loss to
the bloodstream.
In 2008, Balakrishnan et al. [52] assessed how varia-
tions in mural thrombus size and distribution contribute
to fluctuating arterial drug intensities. Their simulations
indicate that thrombus cannot influence the slow rate of
drug release from the stent because the polymer resis-
tance to drug transport is significantly greater than that
of the thrombus, which is consistent with in vivo experi-
mental drug release. Local thrombus, just covering the
strut, of 0.1 mm
2 increased peak average drug concen-
tration and cumulative exposure by 80%. Greater clot
formation between stent struts will also have an effect
on arterial concentrations because once the species is
transported within the clot it effectively increases the
surface area from which the artery wall can absorb
drugs. The formation of this interstrut thrombus,
described as diffuse thrombus, acts as a shield from
drug washout and culminates in an increase in arterial
concentration by up to 3.5-fold [52].
The variability of thrombus can have a major impact
on arterial drug concentrations. It can aid in drug
uptake and retention within the wall when it covers the
stent but too much thrombus will effectively block the
artery, thus creating a problem that the DES aimed to
alleviate. Also it can act as a barrier in preventing drugs
from reaching the wall when it is located between the
stent strut and the wall. The likely scenario following
DES implantation within the vasculature is that at some
location along the length of the stent each of these
situations will be present. A computational approach
considering variations in thrombus formation along the
length of a stent would provide insight into resulting
variations in arterial drug concentrations therein.
Porous media
Drug transport within the vasculature is predominantly
dependent on diffusion and convection. The haemody-
namic nature of blood within the lumen results in con-
vection dominated transport, while MT within the
porous wall is heavily reliant on diffusion. The ratio of
convective to diffusive forces is calculated by the Peclet
number, Pe = vL/D, where v, L and D are the fluid velo-
city, characteristic length and species diffusivity respec-
tively. Physiological Peclet numbers range typically from
0.1 to 10. A small Pe (i.e. Pe << 1) is representative of
transport which is dominated by diffusion, while a
higher Pe (i.e. Pe >> 1) indicates convection dominated
MT [50].
MT within the artery wall was studied in detail prior
to the advent of stent based drug delivery devices in
2003. In 2002, Stangeby and Ethier [6] analysed the
transport of macromolecules, such as low density
Figure 2 Drug eluting stent strut cross-sections. A) is a DES strut with a drug loaded polymer matrix and stent strut B) has a transport
regulating topcoat.
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endothelium and into the wall of a stenosed artery sec-
tion. Subsequent research from Yang and Vafai [60]
examined the effects of hypertension on LDL transport
across each layer of the artery wall. In 2004, Tada and
Tarbell [61] investigated the effects that the IEL has on
macromolecule transport through the wall. Tada and
Tarbell [61] took a more microscopic perspective of the
artery wall than the others by modelling individual
SMC. Although each of these studies differ somewhat,
one thing they have in common is that the artery wall is
treated as a porous structure. This approach may be
applicable in cases of MT from a DES. DES are
deployed in diseased arteries, a result of which is
severely compromised artery wall filtration velocities.
The resulting decrease in the Peclet number will reveal
that MT is diffusion dominated in the artery wall. That
is not to say the porous classification of the artery wall
is no longer relevant when analysing MT from a DES.
In fact the porous nature of any material, biological or
otherwise, will ultimately determine the diffusion rates
within the structure. Therefore any change in the struc-
ture of a porous media will alter its diffusion character-
istics, as is the case for a stent expanding against an
artery wall.
In previous computational studies that analyse the MT
of drugs from stents only a few treat the artery wall as
porous [48,55,57]. In all published research to date, to
the best of the researchers’ knowledge, the change in the
structure of the artery wall under stent compression and
its subsequent effect on drug MT have not been mod-
elled computationally. However O’Connell and Walsh
[62] have demonstrated this effect in an analogous por-
ous material, which indicates that artery wall compres-
sion should be present in all DES computational models.
Stent strut thickness may be vital in minimising the
extent of arterial compression after DES expansion. The
results from the recent SPIRIT-III clinical trials [30]
could be an indication of the influence of strut thickness
on arterial drug distribution and hence the ability to
combat restenosis. It may be possible to develop a com-
putational drug transport model based on these findings,
thus creating a DES for optimal arterial MT. A reported
difference of 60 μm in strut thickness between two differ-
ent stents used in the SPIRIT-III trial may not necessarily
result in 60 μm further compression due to the elastic
nature of the artery. However an exploration into the
extent of compression on the artery wall due to stenting
would exhibit changes in arterial diffusivity compared to
the case of a relaxed artery [62]. This can be attributed to
a reduction in porosity coupled with an increase in tortu-
osity (equation 1) within the artery wall beneath the stent
strut. The result of this relationship, described in
equation 2, is an overall reduction in the effective diffu-
sivity of drugs within the artery wall.
Structural influence of arteries on mass transport
The structure of an artery is unique in that it enables
uninterrupted blood flow throughout the body, provid-
ing the nutrients required for everyday function. For
example its elastic nature enables it to contract and
expand under pulsatile conditions induced from a beat-
ing heart. Along with a healthy endothelial layer to reg-
ulate species progression to the wall, the transport of
such species once within the wall is influenced by the
structure therein. A change in this structure will subse-
quently alter how the species are transported. When a
stent is implanted within an artery it has a major impact
on the structure of the wall. Differences in stent design
will contribute to this because under similar balloon
expansion criteria a thicker stent strut will result in
greater compression of the artery wall. In the SPIRIT-III
clinical trials, the Xience-V stent is 60 μm thinner than
its Taxus counterpart and could be a factor behind its
clinical success thus far. The thinner struts would cause
less compression on the artery wall which in turn would
better aid drug MT. Considering that the medial layer
of the artery wall is only approximately 200 μmt h i c k ,
any reduction in changes to its integrity could yield
positive results. However greater radiopacity and struc-
tural support is achieved with a thicker strut [63].
Arterial properties such as permeability (K), porosity (ε),
tortuosity (τ) and diffusivity (D) dictate the transport of
drugs within the respective wall layers. The compression
of these layers will alter these properties which in turn
may inhibit the transport of species as governed by the
MT equations. The permeability of a material is essentially
its ability to permit the transfer of fluid through it. Perme-
ability ultimately depends on the porosity and tortuosity of
the artery wall and reducing it through wall compression
following stent implantation compromises the arteries’
ability to permit transport of drug.
Porosity (ε) is a dimensionless parameter and is the
ratio of pore volume to the total material volume. Any
porous material under compression will demonstrate a
smaller pore ratio than that of its relaxed state. This in
turn influences the tortuosity (τ) as described by the
pore path through the material. As the tortuosity
increases so too does the effective distance over which
diffusion has to take place [64]. It can be estimated by
the arc-chord ratio, equation 1, which is the ratio of the
actual pore length (L) to the distance between its ends
(X), figure 3.
 
L
X
(1)
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neous and different layers will have different diffusivities.
But the heterogeneity of these layers is highly regular
and as such can be lumped into an effective diffusion
parameter that characterises bulk drug transport within
each respective artery layer [65]. Diffusion is caused by
random molecular motion that eventually leads to com-
plete mixing without the interaction of external forces.
However, in a porous media diffusion takes place in
confined tortuous pores and its progression is impeded
as the tortuosity increases while the porosity decreases.
The effect of pore size coupled with the tortuous nature
of the arterial layers results in an effective diffusion
(Deff) coefficient individual to each of its constituent
layers and can be represented by equation 2 [64].
DD eff Free 


(2)
where DFree is the free diffusivity and can be described
by the Stokes-Einstein equation (3). This relationship
uses molecule size to determine diffusivity.
D
kT
R
Free 
6
(3)
where k is the Boltzmann constant, T is body tem-
perature, μ is fluid viscosity and R is the hydrodynamic
molecule radius.
Conclusions and future work
The shortcomings from PTCA and BMS procedures
have been well documented since the devices became a
prominent treatment of choice for interventional cardi-
ologists in patients with severely stenosed coronary
arteries. The underlying pathology of events such as
restenosis have been investigated and it is widely
accepted that proliferation of SMC from the medial
layer of the artery to the site of injury is the primary
cause of recurring ischemic events. Restenosis is
regarded as a catastrophic failure for cardiovascular
devices such as stents as it increases cost and trauma to
the patient and can cause death if left untreated. The
application of anti-proliferative agents on the surface of
the stent introduced a greater degree of control that had
been lacking in the first generation BMS. Quantification
and associated predictive modelling of drug distribution
from a DES in order to better understand the influence
of arterial variables on MT is essential. This can only be
achieved with realistic experimental validation of mass
transport within a porous media for a range of compres-
sive values. A more comprehensive understanding of the
influences of such variables could lead to an optimal
DES design which could provide a uniform distribution
of drugs within the artery for a patient specific stenosis.
The therapeutic potential of a DES rests with its abil-
ity to distribute drugs evenly within the artery. Histolo-
gical studies of excised stented arteries clearly depict
Figure 3 Determination of tortuosity through a porous material using the arc-chord ratio. The tortuosity of a path through a porous
structure (A) can be determined by the ratio of the pore length, L, to the displacement, X. As can be seen in (B) and (C), the magnitude of L
remains constant but as the compression increases the displacement X reduces to X’ which results in an increase in tortuosity.
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results from the thinner strut Xience-V stent in the
SPIRIT-III clinical trials may explain the extent to
which a decrease in strut thickness can have a positive
effect on the clinical outcome. Knowledge of initial dif-
fusivities for each of the constituent media is not
enough when developing a predictive MT model of DES
within a diseased artery. An iterative method taking into
account the effect of stent strut compression on arterial
diffusivity is required if a comprehensive understanding
is to be achieved. Such improved numerical models of
drug diffusion in arteries will lead to the development of
favourable deployment conditions, responsible for the
amount of artery wall compression, along with the
development of desired drug properties which would
enable the DES to deliver therapeutic quantities of drug
to the artery wall as efficiently as possible.
It is evident that DES have made a major contribution
to minimally invasive interventional cardiology by signif-
icantly reducing restenosis rates. A lack of knowledge
regarding the mechanisms of drug transfer from these
devices once implanted led DES developers to take a
top-down approach to treating the problem. The stents
were coated with ‘enough’ toxic drugs to combat reste-
nosis and would give a beneficial response. This method
had a clear commercial advantage over a slower bot-
tom-up stent design approach, where all factors influen-
cing MT would be assessed and taken into account
during the DES design stage. Since their conception it
has been the greater research community that has dri-
ven the increase in the knowledge base regarding MT
from DES. This paper introduces the issue of compres-
sion mediating artery wall MT that has to date been
overlooked in DES studies.
O’Connell and Walsh [62] examined this effect in an
analogous experimental model and found a 35% decrease
in effective diffusivity within the porous wall when it was
compressed by 23.75%. Although their experiment was
only a 1-D validation it gave insight into how compres-
sion can play an important role in regulating drug distri-
bution within the artery wall. There are two main causes
of concern associated with excessive artery wall compres-
sion. Firstly by reducing the artery wall diffusivity the
drugs fail to distribute sufficiently throughout the artery
wall, resulting in a concentrated dose of drugs beneath
the stent strut. Secondly this excessive drug pooling can
h a v eat o x i ce f f e c to nt h ea r t e r yw a l l .As t u d yb yC h oet
al. in 2006 [66] reported on the ability of paclitaxel to
inhibit human SMC proliferation with concentrations as
low as 0.1 × 10
-3 mol m
-3 to a maximum of 1 × 10
-3 mol
m
-3. However, at the higher concentrations of paclitaxel a
decrease in the proliferative activity of human endothelial
cells was witnessed. Re-endothelialisation is a desired
response after DES implantation and the pooling of
drugs beneath the stent struts may adversely affect this
process.
If a range of deployment conditions for a given stent
design were known prior to implantation then a drug
with a desired artery wall diffusivity could be allocated
and loaded onto a polymer with the appropriate release
characteristics. Likewise if a specific drug had to be
delivered without compromising its diffusivity value
then the stent design could be changed so as to mini-
mise the damage/compression on the artery. As the
hypothesis of compression mediating porous mass trans-
port from DES is in its infancy there remains a substan-
tial amount of work to first validate it in a 3-D arterial
environment and subsequently model it computationally
with the inclusion of the findings from previous studies.
Ongoing studies to address these issues would ulti-
mately result in the completion of a bottom-up under-
standing of the fundamentals of drug MT from a DES.
Acknowledgements
We would like to thank the Irish Research Council for Science, Engineering
and Technology (IRCSET), Grant no. RS/2005/159, for funding this body of
work.
Authors’ contributions
BMOC analysed current literature and prepared the manuscript. TMM revised
the manuscript, MTW supervised the study, revised and gave the final
approval of the manuscript. All authors read and approved the final
manuscript.
Declaration of competing interests
The authors declare that they have no competing interests.
Received: 17 September 2009 Accepted: 9 March 2010
Published: 9 March 2010
References
1. McMahan CA, Gidding SS, McGill HC: Coronary heart disease risk factors
and atherosclerosis in young people. J Clinic Lipid 2008, 2:118-126.
2. Kaazempur-Mofrad MR, Wada S, Myers JG, C.R. Ethier CR: Mass transport
and fluid flow in stenotic arteries: Axisymmetric and asymmetric models.
Int J Heat Mass Tran 2005, 48:4510-4517.
3. Markou CP, Lutostansky EM, Ku DN, Hanson SR: A novel method for
efficient drug delivery. Ann Biomed Eng 1998, 26:502-511.
4. Head DE, Sebranek JJ, Zahed C, Coursin DB, Prielipp RC: A tale of two
stents: Perioperative management of patients with drug-eluting
coronary stents. J Clin Anesth 2007, 19:386-396.
5. Kaul S, Shah P, Diamond GA: As time goes by: Current status and future
directions in the controversy over stenting. J Am Col Cardio 2007,
50:128-137.
6. Stangeby DK, Ethier CR: Computational analysis of coupled blood-wall
arterial LDL transport. J Biomech Eng 2002, 124:1-8.
7. Chen MC, Liang HF, Chiu YL, Chang Y, Wei HJ, Sung HW: A novel drug-
eluting stent spray coated with multi-layers of collagen and sirolimus. J
Control Release 2005, 108:178-189.
8. Yu H, Rifai N: High-sensitivity C-reactive protein and atherosclerosis from
theory to therapy. Clinical Biochem 2000, 33:601-610.
9. Burt HM, Hunter WL: Drug-eluting stents: A multidisciplinary success
story. Adv Drug Deliv Rev 2006, 58:350-357.
10. Chun AA, McGee SR: Bedside diagnosis of coronary artery disease: A
systematic review. Am J Med 2004, 117:334-343.
11. Khakpour M, Vafai K: A comprehensive analytical solution of
macromolecular transport within an artery. Int J Heat Mass Tran 2008,
51:2905-2913.
O’Connell et al. BioMedical Engineering OnLine 2010, 9:15
http://www.biomedical-engineering-online.com/content/9/1/15
Page 10 of 1212. Dumoulin C, Cochelin B: Mechanical behaviour modelling of balloon-
expandable stents. J Biomech 2000, 33:1461-1470.
13. Duraiswamy N, Schoephoerster RT, Moreno MR, Moore JE: Stented artery
flow patterns and their effects on the artery wall. Annu Rev Fluid Mech
2007, 39:357-382.
14. Wada S, Karino T: Theoretical prediction of low-density lipoproteins
concentration at the luminal surface of an artery with a multiple bend.
Annals Biomed Eng 2002, 30:778-791.
15. Deng X, Marois Y, How T, Merhi Y, King M, Guidoin R: Luminal surface
concentration of lipoprotein (LDL) and its effect on the wall uptake of
cholesterol by canine carotid arteries. J Vasc Surg 1995, 21:135-145.
16. Sun N, Wood NB, Hughes AD, Thom SAM, Xu XY: Fluid-wall modelling of
mass transfer in an axisymmetric stenosis: Effects of shear-dependent
transport properties. Annals Biomed Eng 2006, 34:1119-1128.
17. Huang ZJ, Tarbell JM: Numerical simulation of mass transfer in porous
media of blood vessel walls. Am J Physiol 1997, 273:H464-H477.
18. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, Kastrati A,
Schömig A, Wessely R: Local statin therapy differentially interferes with
smooth muscle and endothelial cell proliferation and reduces neointima
on a drug-eluting stent platform. Cardiovas Res 2005, 68:483-492.
19. Rajagopal V, Rockson SG: Coronary restenosis: A review of mechanisms
and management. Am J Med 2003, 115:547-533.
20. Kukreja N, Onuma Y, Daemen J, Serruys PW: The future of drug-eluting
stents. Pharmacol Res 2008, 57:171-180.
21. Hoeven van der BL, Pires NMM, Warda HM, Oemrawsingh PV, van
Vlijmen BJM, Quax PHA, Schalij MJ, Wall van der EE, Jukema JW: Drug
eluting stents: Results, problems and promises. Int J Cardio 2004, 99:9-17.
22. Waksman R: Drug-eluting stents: From bench to bed. Cardiovas Rad Med
2002, 3:226-241.
23. Granada JF, Kaluza GL, Raizner A: Drug-eluting stents for cardiovascular
disorders. Current Athero Rep 2003, 5:308-316.
24. Wang K, Kessler PD, Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Kibbe M,
Kovesdi I, Brough DE, Topol EJ, Lincoff AM: Local adenoviral-mediated
inducible nitric oxide synthase gene transfer inhibits neointimal formation
in the porcine coronary stented model. Molec Ther 2003, 7:597-603.
25. Whelan DM, Giessen van der WJ, Krabbendam SC, van Vliet EA,
Verdouw PD, Serruys PW, van Beusekom HMM: Biocompatibility of
phosphorylcholine coated stents in normal porcine coronary arteries.
Heart 2000, 83:338-345.
26. Rajamohan D, Banerjee RK, Back LH, Ibrahim AA, Jog MA: Developing
pulsatile flow in a deployed coronary stent. J Biomech Eng 2006,
128:347-359.
27. Anis RR, Karsch KR: The future of drug eluting stents. Heart 2006,
92:585-588.
28. Virmani R, Kolodgie FD, Farb A, Lafont A: Drug eluting stents: are human
and animal studies comparable? Heart 2003, 89:133-138.
29. Chung IM, Gold HK, Schwartz SM, Ikari Y, Reidy MA, Wight TN: Enhanced
extracellular matrix accumulation in restenosis of coronary arteries after
stent deployment. J Am Col Cardio 2002, 40:2072-2081.
30. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N,
Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ: Comparison
of an everolimus-eluting stent and a paclitaxel-eluting stent in patients
with coronary artery disease: A randomized trial. JAMA 2008,
299:1903-1913.
31. Mongrain R, Faik I, Leask R, Rodes-Cabau J, Larose E, Bertrand OF: Effects of
diffusion coefficients and strut apposition using numerical simulations
for drug eluting coronary stents. J Biomech Eng 2007, 129:733-742.
32. Costa MA, Simon DI: Molecular basis of restenosis and drug-eluting
stents. Circulation 2005, 111:2257-2273.
33. Welt FG, Rogers C: Inflammation and restenosis in the stent era.
Aterioscler Thromb Vasc Biol 2002, 22:1769-1776.
34. Fattori R, Piva T: Drug-eluting stents in vascular intervention. The Lancet
2003, 361:247-249.
35. Schwartz RS, Chronos NA, Virmani R: Preclinical restenosis models and
drug-eluting stents. J Am Col Cardiol 2004, 44:1373-1385.
36. Yana BPY, Ajania AE, Waksman R: Drug-eluting stents for the treatment of
in-stent restenosis: A clinical review. Cardiov Revas Med 2005, 6:38-43.
37. Indolfi C, Mongiardo A, Curcio A, Torella D: Molecular mechanisms of in-
stent restenosis and approach to therapy with eluting stents. Trends
Cardiovasc Med 2003, 12:142-148.
38. Machan L: Drug eluting stents in the infrainguinal circulation. Techn Vasc
Interv Radio 2004, 7:28-32.
39. Ohtani K, Usui M, Nakano K, Kohjimoto Y, Kitajima S, Hirouchi Y, Li XH,
Kitamoto S, Takeshita A, Egashira K: Antimonocyte chemoattractant
protein-1 gene therapy reduces experimental in-stent restenosis in
hypercholesterolemic rabbits and monkeys. Gene Therapy 2004,
11:1273-1282.
40. Wessely R, Schömig A, Kastrati A: Sirolimus and paclitaxel on polymer-
based drug-eluting stents: Similar but different. J Am Col Cardiol 2006,
47:708-714.
41. Sarembock IJ, Kereiakes DJ: Mechanisms of vascular injury from drug-
eluting stents. Drug Discov Today: Disease Mech 2007, 4:141-146.
42. Auer J, Leitner A, Berent R, Lamm G, Lassnig E, Krennmair G: Long-term
outcomes following coronary drug-eluting- and bare-metal-stent
implantation. Atherosclerosis 2010.
43. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Baki TT,
Little WC: “Off-label” stent therapy: 2-year comparison of drug-eluting
versus bare-metal stents. J Am Coll Cardiol 2008, 51:607-614.
44. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HHT, Bottcher M,
Lassen JF, Krussel LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP,
Soerensen HT, Thuesen L: Stent thrombosis, myocardial infarction, and
death after drug-eluting and bare-metal stent coronary interventions. J
Am Coll Cardiol 2007, 50:463-470.
45. Kamath KR, Barry JJ, Miller KM: The Taxus drug-eluting stent: A new
paradigm in controlled drug delivery. Adv Drug Deliv Rev 2006,
58:412-436.
46. Tanabe K, Regar E, Lee CH, Hoye A, Giessen van der WJ, Serruys PW: Local
drug delivery using coated stents: New developments and future
perspectives. Current Pharma Design 2004, 10:357-368.
47. Venkatraman S, Boey F: Release profiles in drug-eluting stents: Issues and
uncertainties. J Control Release 2007, 120:149-160.
48. Hwang CW, Wu D, Edelman ER: Physiological transport forces govern
drug distribution for stent based delivery. Circulation 2001, 104:600-605.
49. Khakpour M, Vafai K: Critical assessment of arterial transport models. Int J
Heat Mass Trans 2007, 51:807-822.
50. Yang C, Burt HM: Drug-eluting stents: Factors governing local
pharmacokinetics. Adv Drug Deliv Rev 2006, 58:402-411.
51. Zunino P, D’Angelo C, Petrini L, Vergara C, Capelli C, Migliavac F: Numerical
simulation of drug eluting coronary stents: mechanics, fluid dynamics
and drug release. Comput Meth Appl Mech Eng 2009, 198:3633-3644.
52. Balakrishnan B, Dooley JF, Kopia G, Edelman ER: Thrombus causes
fluctuations in arterial drug delivery from intravascular stents. J Control
Release 2008, 131:173-180.
53. Balakrishnan B, Dooley JF, Kopia G, Edelman ER: Intravascular drug release
kinetics dictate arterial drug deposition, retention and distribution.
J Control Release 2007, 123:100-108.
54. Balakrishnan B, Tzafriri AR, Seifert P, Groothuis A, Rogers C, Edelman ER:
Strut position, blood flow, and drug deposition: Implications for single
and overlapping drug-eluting stents. Circulation 2005, 111:2958-2965.
55. Pontrelli G, de Monte F: Mass diffusion through two-layered porous
media: An application to the drug-eluting stent. Int J Heat Mass Trans
2007, 50:3658-3669.
56. Acharya G, Park K: Mechanisms of controlled drug release from drug-
eluting stents. Adv Drug Del Rev 2006, 58:387-401.
57. Zunino P: Multidimensional pharmacokinetic models applied to the
design of drug-eluting stents. Cardiovasc Eng: An Int J 2004, 4:181-191.
58. Mongrain R, Leask R, Brunette J, Faik I, Bulman-Feleming N, Nguyen T:
Numerical modeling of coronary drug eluting stents. Stud Health Technol
Inform 2005, 113:443-458.
59. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER: Thrombosis modulates
arterial drug distribution for drug eluting stents. Circulation 2005,
111:1619-1626.
60. Yang N, Vafai K: Modeling of low-density lipoprotein (LDL) transport in
the artery–effects of hypertension. Int J Heat Mass Trans 2006, 49:850-867.
61. Tada S, Tarbell JM: Internal elastic lamina affects the distribution of
macromolecules in the arterial wall: a computational study. Am J Physiol
Heart Circ Physiol 2004, 281:H905-H913.
62. O’Connell BM, Walsh MT: Demonstrating the influence of compression on
artery wall mass transport. Ann Biomed Eng 2010.
O’Connell et al. BioMedical Engineering OnLine 2010, 9:15
http://www.biomedical-engineering-online.com/content/9/1/15
Page 11 of 1263. Hara H, Nakamura M, Palmaz JC, Schwartz RS: Role of stent design and
coatings on restenosis and thrombosis. Adv Drug Del Rev 2006,
58:377-386.
64. Cussler EL: Diffusion Mass Transfer in Fluid Systems Cambridge, University
Press, 2 2005.
65. Hwang CW, Edelman ER: Arterial ultrastructure influences transport of
locally delivered drugs. Circulation 2002, 90:826-832.
66. Cho HJ, Kim TY, Cho HJ, Park KW, Zhang SY, Kim JH, Kim SH, Hahn JY,
Kang HJ, Park YB, Kim HS: The effect of stem cell mobilization by
granulocyte-colony stimulating factor on neointimal hyperplasia and
endothelial healing after vascular injury with bare-metal versus
paclitaxel-eluting stents. J Am Coll Cardiol 2006, 48:366-374.
doi:10.1186/1475-925X-9-15
Cite this article as: O’Connell et al.: Factors that affect mass transport
from drug eluting stents into the artery wall. BioMedical Engineering
OnLine 2010 9:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
O’Connell et al. BioMedical Engineering OnLine 2010, 9:15
http://www.biomedical-engineering-online.com/content/9/1/15
Page 12 of 12